ArticleNagoya journal of medical science2016
Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis.
Article in Nagoya journal of medical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- [Neurological side effects of checkpoint inhibitors].Der Nervenarzt · 2019Pooled it
- Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.Current neurology and neuroscience reports · 2023Review
- Neurologic Complications of Cancer Immunotherapy.Current oncology (Toronto, Ont.) · 2023Review
- Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.Investigational new drugs · 2023Article
- Ocular adverse events associated with immune checkpoint inhibitors, a scoping review.Journal of ophthalmic inflammation and infection · 2023Article
- Immune checkpoint inhibitors for patients with pre-existing autoimmune diseases.Nagoya journal of medical science · 2023Article
- Review
- Considering Computational Mathematics IGHG3 as Malignant Melanoma Is Associated with Immune Infiltration of Malignant Melanoma.BioMed research international · 2022Article
- Myasthenia gravis induced or exacerbated by immune checkpoint inhibitors: a rising concern.BMJ case reports · 2021Article
- Immunotherapy use outside clinical trial populations: never say never?Annals of oncology : official journal of the European Society for Medical Oncology · 2021Review
- Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update.Journal of clinical medicine · 2021Review
- Neurologic Toxicities of Immunotherapy.Advances in experimental medicine and biology · 2021Article
- Neurologic Toxicities of Cancer Immunotherapies: a Review.Current neurology and neuroscience reports · 2020Review
- Neurologic complications of immune checkpoint inhibitors.Expert opinion on drug safety · 2020Review
- Immune Checkpoint Inhibitor-Induced Myasthenia Gravis.Frontiers in neurology · 2020Review
- Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders.Frontiers in medicine · 2020Review
- Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.Eye and brain · 2020Review
- Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.Current oncology reports · 2019Review
- Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.Drug safety · 2019Review
- Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia.Annals of clinical and translational neurology · 2018Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 79-year-old man with lymph node recurrence of malignant melanoma received nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody. He had pre-existing ocular myasthenia gravis (MG) and a continued small amount of corticosteroid. Grade 3 creatine phosphokinase elevation appeared after two doses of nivolumab, and the treatment was postponed until it improved to grade 1. After three doses of nivolumab, he experienced diplopia and facial muscle weakness which were consistent with an acute exacerbation of MG, and the symptoms relieved without additional treatment for MG. He achieved shrinkage of metastasis after ten doses of nivolumab. Although a case who died due to MG after administration of nivolumab was reported recently, pre-existing MG is considered not to be always a contraindication of nivolumab.
Indexed as
Identifiers
27019533PMC4767520W2346969436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.